Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?
Epcoritamab, a cancer drug co-developed by (NYSE: ABBV) and Genmab (NASDAQ: GMAB), was recently given the green light by the Food and Drug Administration to be used as a treatment for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
What could this news mean for patients diagnosed with R/R DLBCL? And how much of a lift in sales could it provide to the pharmaceutical companies? Let's drill down into the efficacy of epcoritamab (marketed as Epkinly) and this specific lymphoma market to find out.
Of all blood cancers, lymphoma is the most common. The disease impacts lymphocytes, which are a type of white blood cell that protects the body from bacteria and viruses. Lymphoma generally happens when lymphocytes mutate, which leads to a cell replicating more rapidly than a normal lymphocyte.
Source Fool.com
AbbVie Inc. Stock
With 32 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 180 € there is a slightly positive potential of 7.09% for AbbVie Inc. compared to the current price of 168.08 €.
